MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients

Although imatinib is highly effective in the treatment of chronic myeloid leukemia (CML), 25–30% patients do not respond or relapse after initial response. Imatinib uptake into targeted cells is crucial for its molecular response and clinical effectiveness. The organic cation transporter 1 (OCT1) ha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Cancer J
Autors principals: Harrach, S, Schmidt-Lauber, C, Pap, T, Pavenstädt, H, Schlatter, E, Schmidt, E, Berdel, W E, Schulze, U, Edemir, B, Jeromin, S, Haferlach, T, Ciarimboli, G, Bertrand, J
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5056971/
https://ncbi.nlm.nih.gov/pubmed/27635733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2016.79
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars